Broker Recommendation
Analysts at Goldman Sachs downgraded FMC (NYSE: FMC) from “neutral” to “sell.” The target price for FMC has been lowered from $63 to $58.

FMC's shares closed at $62.32 on Friday.

Breaking news

McAfee today reached a major milestone in its acquisition of Stonesoft Oyj by completing the tender offer that was announced on May 6. To read the full news, click here.

ING (NYSE: ING) announced today that it has agreed to sell its 50% stake in its Chinese insurance joint venture ING-BOB Life Insurance Company to BNP Paribas Cardif, the insurance arm of BNP Paribas (OTC: BNPQY). To read the full news, click here.

Novartis (NYSE: NVS) today announced that it has entered into a development and licensing agreement with Biological E Limited (BioE), a biopharmaceutical company based in India, for two vaccines to protect against typhoid and paratyphoid fevers. To read the full news, click here.

Astex Pharmaceuticals (NASDAQ: ASTX) announced today its plan to submit an Investigational New Drug or IND application to the Food and Drug Administration (FDA) for ASTX727, a novel oral hypomethylating agent (HMA) in the fourth quarter of this year. To read the full news, click here.